These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 24338002)
1. Why anti-Bcl-2 clinical trials fail: a solution. Harazono Y; Nakajima K; Raz A Cancer Metastasis Rev; 2014 Mar; 33(1):285-94. PubMed ID: 24338002 [TBL] [Abstract][Full Text] [Related]
2. Targeting the B-cell lymphoma/leukemia 2 family in cancer. Davids MS; Letai A J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144 [TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics to improve cancer therapy; mechanisms and examples. Zhang L; Ming L; Yu J Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043 [TBL] [Abstract][Full Text] [Related]
4. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. Song JH; Kandasamy K; Kraft AS J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488 [TBL] [Abstract][Full Text] [Related]
5. [Effect and significance of BH3-only protein in targeted therapy of non-small cell lung cancer]. Gao W; Huang W; Liu K Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):819-23. PubMed ID: 25404273 [TBL] [Abstract][Full Text] [Related]
6. Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer. Fairlie WD; Lee EF Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799592 [TBL] [Abstract][Full Text] [Related]
7. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Labi V; Grespi F; Baumgartner F; Villunger A Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371 [TBL] [Abstract][Full Text] [Related]
8. Restoring cancer's death sentence. Letai A Cancer Cell; 2006 Nov; 10(5):343-5. PubMed ID: 17097553 [TBL] [Abstract][Full Text] [Related]
9. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Vogler M; Dinsdale D; Dyer MJ; Cohen GM Cell Death Differ; 2009 Mar; 16(3):360-7. PubMed ID: 18806758 [TBL] [Abstract][Full Text] [Related]
11. The role of galectin-3 in cancer drug resistance. Fukumori T; Kanayama HO; Raz A Drug Resist Updat; 2007 Jun; 10(3):101-8. PubMed ID: 17544840 [TBL] [Abstract][Full Text] [Related]
13. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435 [TBL] [Abstract][Full Text] [Related]
14. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Takenaka Y; Fukumori T; Yoshii T; Oka N; Inohara H; Kim HR; Bresalier RS; Raz A Mol Cell Biol; 2004 May; 24(10):4395-406. PubMed ID: 15121858 [TBL] [Abstract][Full Text] [Related]
15. Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. Hall C; Troutman SM; Price DK; Figg WD; Kang MH Clin Genitourin Cancer; 2013 Mar; 11(1):10-9. PubMed ID: 23083798 [TBL] [Abstract][Full Text] [Related]
16. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Kang MH; Reynolds CP Clin Cancer Res; 2009 Feb; 15(4):1126-32. PubMed ID: 19228717 [TBL] [Abstract][Full Text] [Related]